Health
Immunotherapy drug improves survival over standard chemotherapy for lung cancer patients – News-Medical.Net
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), acco…
Reviewed by Emily Henderson, B.Sc.Oct 1 2020
The immunotherapy drug atezolizumab improves survival over standard chemotherapy for many patients with newly diagnosed non-small cell lung cancer (NSCLC), according to a new study led by Yale Cancer Center (YCC) researchers.
The findings, from a global randomized phase 3 clinical trial published today in the New England Journal of Medicine, support the U.S. Food and Drug Administration’s approval of the drug for this indication in May.
These are e…
-
General11 hours agoByford rail extension opening marks final stage of Perth Metronet
-
Noosa News17 hours agoFatal traffic crash, Baringa – Sunshine Coast
-
General23 hours agoBritish and US planes fly 12-hour mission to patrol Russian border
-
General13 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery